{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:04:33Z","timestamp":1790366673658,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Diag Ther"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/bf03256419","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T03:39:09Z","timestamp":1345174749000},"page":"277-283","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacogenetics of Oxaliplatin as Adjuvant Treatment in Colon Carcinoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Arantza Fari\u00f1a","family":"Sarasqueta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesina","family":"van Lijnschoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery E. P. P.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm J. T.","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan J. C.","family":"van den Brule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,16]]},"reference":[{"issue":"2","key":"BF03256419_CR1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ctrv.2004.12.006","volume":"31","author":"DM Kweekel","year":"2005","unstructured":"Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005 Apr; 31(2): 90\u2013105","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"BF03256419_CR2","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004 Jun 3; 350(23): 2343\u201351","journal-title":"N Engl J Med"},{"issue":"16","key":"BF03256419_CR3","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007 Jun 1; 25(16): 2198\u2013204","journal-title":"J Clin Oncol"},{"issue":"10","key":"BF03256419_CR4","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/j.1572-0241.2006.00775.x","volume":"101","author":"DP Cronin","year":"2006","unstructured":"Cronin DP, Harlan LC, Potosky AL, et al. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 2006 Oct; 101(10): 2308\u201318","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"BF03256419_CR5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/annonc\/mdp482","volume":"21","author":"LN Steenbergen van","year":"2010","unstructured":"van Steenbergen LN, Rutten HJ, Creemers GJ, et al. Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Ann Oncol 2010 Jun; 21(6): 1273\u20138","journal-title":"Ann Oncol"},{"issue":"1","key":"BF03256419_CR6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007 Feb; 33(1): 9\u201323","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"BF03256419_CR7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008 Mar 1; 14(5): 1291\u20135","journal-title":"Clin Cancer Res"},{"key":"BF03256419_CR8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.bjc.6601975","volume":"91","author":"J Stoehlmacher","year":"2004","unstructured":"Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344\u201354","journal-title":"Br J Cancer"},{"issue":"6","key":"BF03256419_CR9","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1078-0432.CCR-10-2169","volume":"17","author":"M Yin","year":"2011","unstructured":"Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2\/XPD polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 2011 Mar 15; 17(6): 1632\u201340","journal-title":"Clin Cancer Res"},{"issue":"26","key":"BF03256419_CR10","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2006.05.8768","volume":"24","author":"M Quintela-Fandino","year":"2006","unstructured":"Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006 Sep 10; 24(26): 4333\u20139","journal-title":"J Clin Oncol"},{"issue":"8","key":"BF03256419_CR11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/FPC.0b013e32832f3010","volume":"19","author":"PA Bradbury","year":"2009","unstructured":"Bradbury PA, Kulke MH, Heist RS, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009 Aug; 19(8): 613\u201325","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"BF03256419_CR12","first-page":"1354","volume":"61","author":"MR Spitz","year":"2001","unstructured":"Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001 Feb 15; 61(4): 1354\u20137","journal-title":"Cancer Res"},{"key":"BF03256419_CR13","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1158\/1078-0432.CCR-05-1363","volume":"12","author":"V Moreno","year":"2006","unstructured":"Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006 Apr 1; 12 (7 Pt 1): 2101\u20138","journal-title":"Clin Cancer Res"},{"issue":"7","key":"BF03256419_CR14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/sj.bjc.6604671","volume":"99","author":"L Pare","year":"2008","unstructured":"Pare L, Marcuello E, Altes A, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin\/ 5-fluorouracil as first-line chemotherapy. Br J Cancer 2008 Oct 7; 99(7): 1050\u20135","journal-title":"Br J Cancer"},{"issue":"24","key":"BF03256419_CR15","first-page":"8654","volume":"61","author":"DJ Park","year":"2001","unstructured":"Park DJ, Stoehlmacher J, Zhang W, et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001 Dec 15; 61(24): 8654\u20138","journal-title":"Cancer Res"},{"issue":"3","key":"BF03256419_CR16","first-page":"162","volume":"1","author":"DJ Park","year":"2003","unstructured":"Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003 Mar; 1(3): 162\u20136","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"BF03256419_CR17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2006.08.1844","volume":"25","author":"A Ruzzo","year":"2007","unstructured":"Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007 April 1; 25(10): 1247\u201354","journal-title":"J Clin Oncol"},{"issue":"17","key":"BF03256419_CR18","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-04-2216","volume":"11","author":"J Viguier","year":"2005","unstructured":"Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin\/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005 Sep 1; 11(17): 6212\u20137","journal-title":"Clin Cancer Res"},{"key":"BF03256419_CR19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2407-8-50","volume":"8","author":"MY Huang","year":"2008","unstructured":"Huang MY, Fang WY, Lee SC, et al. ERCC2 2251 A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer 2008; 8: 50","journal-title":"BMC Cancer"},{"issue":"3","key":"BF03256419_CR20","first-page":"555","volume":"16","author":"JJ Yu","year":"2000","unstructured":"Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780\/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000 Mar; 16(3): 555\u201360","journal-title":"Int J Oncol"},{"issue":"4","key":"BF03256419_CR21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/carcin\/21.4.551","volume":"21","author":"RM Lunn","year":"2000","unstructured":"Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000 Apr; 21(4): 551\u20135","journal-title":"Carcinogenesis"},{"issue":"4","key":"BF03256419_CR22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ejca.2008.10.015","volume":"45","author":"DM Kweekel","year":"2009","unstructured":"Kweekel DM, Gelderblom H, Antonini NF, et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 2009 Mar; 45(4): 572\u20138","journal-title":"Eur J Cancer"},{"issue":"20","key":"BF03256419_CR23","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.1158\/1078-0432.CCR-09-0877","volume":"15","author":"A Hendifar","year":"2009","unstructured":"Hendifar A, Yang D, Lenz F, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009 Oct 15; 15(20): 6391\u20137","journal-title":"Clin Cancer Res"},{"issue":"12","key":"BF03256419_CR24","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1007\/DCR.0b013e3181beb42a","volume":"52","author":"EC Paulson","year":"2009","unstructured":"Paulson EC, Wirtalla C, Armstrong K, et al. Gender influences treatment and survival in colorectal cancer surgery. Dis Colon Rectum 2009 Dec; 52(12): 1982\u201391","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"BF03256419_CR25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/BF02237397","volume":"41","author":"C Ratto","year":"1998","unstructured":"Ratto C, Sofo L, Ippoliti M, et al. Prognostic factors in colorectal cancer: literature review for clinical application. Dis Colon Rectum 1998 Aug; 41(8): 1033\u201349","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"BF03256419_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/pgs.10.163","volume":"12","author":"MA Gordon","year":"2010","unstructured":"Gordon MA, Zhang W, Yang D, et al. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 2010 Jan; 12(1): 27\u201339","journal-title":"Pharmacogenomics"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03256419\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T18:54:08Z","timestamp":1562093648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03256419"}},"subtitle":["Are Single Nucleotide Polymorphisms in GSTP1, ERCC1, and ERCC2 Good Predictive Markers?"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["BF03256419"],"URL":"https:\/\/doi.org\/10.1007\/bf03256419","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}